Why the study?
Does low-molecular-weight heparin reduce the incidence of deep venous thrombosis in patients undergoing hip fracture surgery?
Does low-molecular-weight heparin reduce the incidence of deep venous thrombosis in patients undergoing hip fracture surgery?
A once-daily 5000 IU subcutaneous dose of low-molecular-weight heparin provides effective and safe thromboprophylaxis in patients undergoing hip fracture surgery.
LMWH supports routine thromboprophylaxis after hip fracture surgery; confirms DVT prevention benefit in this RCT population.
A prospective, randomized, double-blind trial concerning thromboprophylaxis in 82 patients in whom hip fracture surgery was performed was conducted to compare a new low-molecular-weight heparin (Fragmin) with placebo. Deep venous thrombosis (DVT) was detected by 125-I-fibrinogen uptake test followed by ascending phlebography when positive. Sixty-eight patients completed the study, and a 50% reduction in the incidence of DVT was demonstrated: nine of 30 patients in the treatment group (30%) and 22 of 38 patients in the placebo group (58%) developed DVT. This significant difference was achieved by one daily dose of 5000IU Fragmin subcutaneously, commenced preoperatively and continued for six days. There were no differences in bleeding or other complications in the two groups. Fragmin given once daily offers an effective and safe thromboprophylaxis in hip fracture surgery.
No takes yet. Share an insight, caveat, or question.
Ps et al. (1992) studied this question.